Empire Genomics (Empire) is a provider of genomic reagents and clinical testing services headquartered in Buffalo, New York.
Founded in 2006 at the prestigious Roswell Park Cancer institute, Empire played a fundamental role in the Human Genome Project and created the foundational Bacterial Artificial Chromosomes (BACs) that served as the basis for sequencing the genome. The company is a pioneer in the commercialization of the genomic biomarker, positioning itself as a resource for genetics and oncology researchers and a partner to the biopharmaceutical industry and physicians, with the goal of personalizing medicine to improve patients’ health.
Empire’s genomics division’s primary focus is the development and manufacturing of custom fluorescence in situ hybridization (FISH) probes, as well as solid tumor probes, loci specific probes and control probes. Products and services also include BAC Clones (bacterial slabs or purified DNA); Genotyping (SNP analysis); Circulating Tumor Cells; and custom services to meet unique research or clinical needs.
Empire’s clinical services division offers an integrated approach focused on providing diagnostic, prognostic, therapeutic and disease-monitoring information for the oncology market. The company’s fully certified facility and collaborative approach enables personalized medicine by making advanced clinical disease management tools available to oncologists, pathologists and cytogenetic groups.